BiotechTube

Trastuzumab deruxtecan

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer

Conditions

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Trial Timeline

Aug 18, 2020 → Jul 30, 2027

NCT ID
NCT04482309

About Trastuzumab deruxtecan

Trastuzumab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04482309. Target conditions include Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer were approved

Approved (20) Terminated (4) Active (0)
✅Perampanel + PlaceboEisaiApproved
✅Adjunctive Zonisamide + Replacement with ZonisamideEisaiApproved
✅PerampanelEisaiApproved
✅Eslicarbazepine acetate + Eslicarbazepine AcetateSumitomo PharmaApproved
✅DoravirineMerckApproved
✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved
✅OxcarbazepineNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (19)

NCT IDPhaseStatus
NCT07015697Phase 1Recruiting
NCT06750484Phase 2Recruiting
NCT05982678Phase 2Recruiting
NCT06386263Pre-clinicalCompleted
NCT06210776Pre-clinicalRecruiting
NCT05950945Phase 3Recruiting
NCT05993234Pre-clinicalRecruiting
NCT05945732Pre-clinicalRecruiting
NCT05458401Pre-clinicalCompleted
NCT05246514Phase 2Active
NCT04989816Phase 2Completed
NCT04739761Phase 3Active
NCT04644237Phase 2Completed
NCT04639219Phase 2Active
NCT04482309Phase 2Recruiting
NCT04752059Phase 2Completed
NCT04420598Phase 2Completed
NCT04014075Phase 2Completed
NCT03505710Phase 2Terminated

Competing Products

20 competing products in Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Use of Wearable Digital Sensors After mRNA Vaccination in AdultsModernaPreclinical
0
mRNA-0184ModernaPhase 1
0
mRNA-0184ModernaPhase 1
0
LY2409021Eli LillyPhase 1
29
IxekizumabCelltrionPhase 1
33
YH35995 + PlaceboYuhanPhase 1
36
ASP8731 + ASP8731 Matching PlaceboAstellas PharmaPhase 1
21
EnsitrelvirShionogiPhase 1
29
Rosuvastatin + BPN14770ShionogiPhase 1
29
S-892216-LAI + PlaceboShionogiPhase 1
36
S-740792 Suspension + Midazolam + Placebo + S-740792 TabletShionogiPhase 1
29
E6130 + PlaceboEisaiPhase 1
21
E2007EisaiPhase 3
40
E6130 + PlaceboEisaiPhase 1
29
E7386EisaiPhase 1
29
PerampanelEisaiPre-clinical
26
perampanel + perampanelEisaiPhase 1
29
perampanel + perampanel + perampanel + PlaceboEisaiPhase 3
40
Perampanel + PlaceboEisaiApproved
35
Perampanel + PerampanelEisaiPhase 1
29